We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-5.71%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$810M
AUM Growth
-$260M
Cap. Flow
-$189M
Cap. Flow %
-23.28%
Top 10 Hldgs %
32%
Holding
105
New
11
Increased
30
Reduced
42
Closed
19

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$17.2M
2
VEEV icon
Veeva Systems
VEEV
+$16.8M
3
BSX icon
Boston Scientific
BSX
+$15.5M
4
ABT icon
Abbott
ABT
+$12.6M
5
WAY
Waystar Holding Corp
WAY
+$9.09M

Top Sells

Rank Stock Value
1
COO icon
Cooper Companies
COO
+$22M
2
VERA icon
Vera Therapeutics
VERA
+$21.3M
3
MDT icon
Medtronic
MDT
+$19.7M
4
DHR icon
Danaher
DHR
+$17.2M
5
ALGN icon
Align Technology
ALGN
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
76
Ocular Therapeutix
OCUL
$1.89B
$2.58M 0.32%
305,000
+40,000
+15% +$381K
STE icon
77
Steris
STE
$22.7B
$2.54M 0.31%
11,500
+5,500
+92% +$1.35M
VCEL icon
78
Vericel Corp
VCEL
$2.37B
$2.25M 0.28%
70,000
-47,000
-40% -$1.67M
KURA icon
79
Kura Oncology
KURA
$841M
$2.21M 0.27%
271,500
-600,500
-69% -$5.16M
CI icon
80
Cigna
CI
$72.4B
$2.13M 0.26%
8,000
-30,650
-79% -$8.48M
BTSG icon
81
BrightSpring Health Services
BTSG
$12.4B
$2.13M 0.26%
50,000
-148,000
-75% -$5.96M
XENE icon
82
Xenon Pharmaceuticals
XENE
$6.19B
$1.63M 0.2%
28,000
-111,000
-80% -$5.11M
ALGN icon
83
Align Technology
ALGN
$12.4B
$1.29M 0.16%
7,500
-91,500
-92% -$16M
NVCR icon
84
NovoCure
NVCR
$1.89B
$763K 0.09%
+70,000
New +$874K
ATEC icon
85
Alphatec Holdings
ATEC
$1.59B
$762K 0.09%
70,000
+50,000
+250% +$728K
CMPX icon
86
Compass Therapeutics
CMPX
$357M
$609K 0.08%
+115,113
New +$664K
ACLX
87
DELISTED
Arcellx
ACLX
– –
-133,500
Closed -$8.7M
APLS
88
DELISTED
Apellis Pharmaceuticals
APLS
– –
-374,450
Closed -$9.41M
BNTX icon
89
BioNTech
BNTX
$23.1B
– –
-20,870
Closed -$1.99M
BRKR icon
90
Bruker
BRKR
$7.66B
– –
-147,315
Closed -$6.94M
CNC icon
91
Centene
CNC
$31.7B
– –
-46,231
Closed -$1.9M
CNTA
92
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-100,000
Closed -$2.5M
CYTK icon
93
Cytokinetics
CYTK
$10.7B
– –
-44,375
Closed -$2.82M
INSP icon
94
Inspire Medical Systems
INSP
$1.85B
– –
-35,800
Closed -$3.3M
IRTC icon
95
iRhythm Holdings
IRTC
$4.18B
– –
-7,000
Closed -$1.24M
JANX icon
96
Janux Therapeutics
JANX
$973M
– –
-225,377
Closed -$3.11M
PEN icon
97
Penumbra
PEN
$12.8B
– –
-31,500
Closed -$9.79M
PRVA icon
98
Privia Health
PRVA
$3B
– –
-125,000
Closed -$2.96M
QURE icon
99
uniQure
QURE
$3.03B
– –
-79,375
Closed -$1.9M
RDNT icon
100
RadNet
RDNT
$5.44B
– –
-47,000
Closed -$3.35M
1 2 3
4
5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Rhenman & Partners Asset Management held 105 positions worth $810M, down 24% from $1.07B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $189M in Q1 2026, closing 19 positions and reducing 42 holdings. Its most notable exit was Vera Therapeutics, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Stryker worth $15.7M.

  • Rhenman & Partners Asset Management's largest Q1 2026 buy was Stryker: 47,800 shares worth $15.7M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q1 2026, an estimated $15.5M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2026 reduction was Cooper Companies, cutting an estimated $22M.
  • Rhenman & Partners Asset Management fully exited Vera Therapeutics in Q1 2026, selling an estimated $21.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $810M portfolio in Q1 2026.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 19 in Q1 2026.
  • Rhenman & Partners Asset Management's portfolio value fell 24% quarter-over-quarter to $810M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.